Priof. Heiner Wedemeyer, MD has been Professor and Chairman of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School since April 1, 2020. He was Professor and Chairman of the Department of Gastroenterology and Hepatology at the University Clinic Essen between February 2019 and April 2020.
Prof. Robert S. Brown, Jr., MD, MPH is Vice-Chair of Transitions of Care and Clinical Chief of the Division of Gastroenterology and Hepatology in the Department of Medicine Weill Cornell Medical College in New York, New York. He is also a Professor of Clinical Medicine at Columbia University College of Physicians & Surgeons. Dr. Brown is the Director of the Center for Liver Disease and Transplantation at New York-Presbyterian Hospital in New York. In this video, Dr. Prof Brown has summarized the concept of Hepato Renal Syndrome, its pathogenesis, and potential treatment options.
Dr. Levy is a Professor of Medicine, board-certified in Gastroenterology (recertified in 2016) and Transplant Hepatology (certified in 2012). Dr. Levy is the Associate Director of the Schiff Center for Liver Diseases and was awarded the Arthur Hertz Endowed Chair in Liver Diseases.
Dr. Levy’s clinical research program focuses on cholestatic and autoimmune liver diseases, with emphasis on clinical trial design and conduct. She is a member of the steering committee for the International Primary Sclerosing Cholangitis Study group (IPSCSG) and serves as the Chair for the TARGET-Primary Biliary Cholangitis (PBC) national registry. Dr. Levy currently serves as a member of the Practice Guidelines Committee for the American Association for the Study of Liver Diseases (AASLD). She co-authored the new AASLD Practice Guidance document for PBC and has published over 120 original articles, reviews and editorials, in addition to book chapters. Dr Levy is also a site-PI for the NIH Porphyrias Consortium and a founding member of the APEX (American Porphyria Experts Collaborative).
Previously, Dr. Levy served as an Assistant Professor of Medicine with the Division of Gastroenterology, Hepatology and Nutrition at the University of Florida and the Malcolm Randall VAMC in Gainesville, FL. She was the Program Director for Transplant Hepatology Fellowship at University of Miami between 2012 and 2019.
Dr. Levy received her M.D. from Universidade Federal do Rio de Janeiro (UFRJ). She completed house staff training both at her home University and subsequently at University of Miami/Jackson Memorial Hospital, in Miami, FL. Dr. Levy completed her 3-year Gastroenterology Fellowship at Mayo Clinic in Rochester, Minnesota, and a 1-year Transplant Hepatology Fellowship at University of Florida, in Gainesville, FL.
John M Vierling MD, FACP, FAASLD, AGAF is Professor of Medicine and Surgery and Chief of Hepatology and Director of Baylor Liver Health at the Baylor College of Medicine in Houston, Texas. He also serves as Director of Advanced Liver Therapies (a clinical research unit) and Program Director of the Hepatology and Liver Transplantation Fellowship. He graduated from Stanford University with a degree in Biology with Great Distinction and received his M.D. degree from Stanford University School of Medicine. He was a Clinical Associate in the Liver Unit at NIH prior to completing a Gastroenterology Fellowship at UC, San Francisco. He was the founding Medical Director of the Liver Transplantation programs at the University of Colorado Health Sciences Center and at Cedars-Sinai/UCLA. His clinical interests include autoimmune and alloimmune liver diseases, liver transplantation, acute liver failure, viral hepatitis, non-alcoholic fatty liver disease, Wilson disease and drug-induced liver injury (DILI). His translational research interest is immunologic mechanisms of hepatobiliary injury. He has authored over 290 manuscripts and chapters. He is co-editor of Liver Immunology: Principles and Practice, now in its 3rd edition. He has served on the Editorial Boards of Hepatology, Liver Transplantation and Gastroenterology. Honors include Phi Beta Kappa, Alpha Omega Alpha, Best Doctors in America for the past 21 years, Top 1% physician rating by U.S. News and World Report, Who’s Who in America, in the World, in Science and Engineering, in Healthcare, the Albert Nelson Marquis Lifetime Achievement Award and the 2021 AASLD Distinguished Service Award. He currently serves on the NIH NIDDK Liver Tissue and Cell Distribution System Coordinating Committee and on the DILI Network’s DSMB. He has also served as President of the American Association for the Study of Liver Diseases, Secretary-Treasurer of Digestive Disease Week® and Chairman of the National Board of Directors of the American Liver Foundation to advance the science and practice of hepatology.
Prof. Gulnara Aghayeba, PhD., M.D. is currently the Head of the Liver Diseases Department at the Baku Health Center, Baku, Azerbaijan. She is the current President of the Azerbaijan Gastroenterologists and Hepatologists Association. Her work focuses on Hepatitis Delta virus infection, and in 2019 she remained as the President of APASL Single Theme Conference on “Delta Hepatitis” infection.
Mauro Bernardi has been a full professor of Internal Medicine at Bologna University and director of Semeiotica Medica, a unit of Internal Medicine at the University Hospital S. Orsola in Bologna until October 31, 2017, when he retired. He is now Professor Emeritus of Internal Medicine at Bologna University. His past academic duties at Bologna University include the directions of the Postgraduate School in Internal Medicine, the Institute of Patologia Speciale Medica, and the Department of Internal Medicine, Cardioangiology, Hepatology. He has been chairman of the Teaching Commission of the Faculty of Medicine and Surgery and the University Research Observatory. At present, he is the chairman of the Bioethics Committee. Professor Bernardi has been a member of the Scientific Committees of the Italian Association for the Study of the Liver and the European Association for the Study of the Liver. He has been treasurer of the European Association for the Study of the Liver and vice-chairman of the European Consortium for the study of Chronic Liver Failure. His main research field is represented by Hepatology, with particular interests in cirrhosis, portal hypertension and related complications, hepatocellular carcinoma, chronic viral hepatitis, and liver transplantation. He has co-authored more than 450 full papers and letters-to-the-editor published in peer-reviewed journals quoted by JCR with a total impact factor of about 5,600 and H-index 81 (Scopus).
Prof. Mohammad Sultan Khuroo graduated from Medical College Srinagar Kashmir, India in 1967. He completed his postgraduate degree in General Medicine (MD) from Medical College Srinagar in 1972 and DM in Gastroenterology from post- graduate Institute of Medical Education & Research, (PGIMER) Chandigarh, Punjab, India (June 1976 to June 1978). During his training period he described the syndrome of “Hepatic vein thrombosis following pregnancy” and published this work in a coveted paper in “American Journal of Medicine (1980; 68:113)”. He returned to Medical College Srinagar, Kashmir, India in June 1978. He was soon rewarded for his actions as he discovered “Hepatitis E” as a new disease entity (American Journal Medicine 1980; 68:818) and spent his next 40 years in exploring the intriguing behavior of this entity and its agent (Hepatitis E virus). It is heartening to learn that Prof. Khuroo spent money generated from his private practice to fund for research projects on “Hepatitis E” (the projects received no funding from any other source). The Discovery of Hepatitis E brought him national and international fame, recognition, and innumerable awards and stamped his position in “History of Medicine” as a Discoverer. In 1982, Prof. Khuroo joined the Chair in the Department of Medicine and Gastroenterology at the “Sher-I-Kashmir Institute of Medical Sciences Srinagar, Kashmir, India (SKIMS)” and held the position of Dean Medical Faculty (1985-1986) and Director SKIMS (1993-1995). During 13 years at SKIMS, he discovered the disease entity of “Hepato-Biliary Pancreatic Ascariasis”, established the role of proton pump inhibitors in peptic ulcer bleeding, described percutaneous drainage of hepatic hydatidosis (commonly known as PAIR technique), and recognized the syndrome of portal biliopathy. Prof. Khuroo build up a strong research team at the SKIMS and did extensive epidemiological studies on the peptic ulcers, gall stones, and esophageal and gastric cancer, and established State of Jammu & Kashmir in the epidemiological map as a zone for distinctive disease patterns. He collaborated with national and international research centers to do basic research on hepatitis E, esophageal and gastric cancer, and biliary disease. In his capacity as a clinician and administrator, he immensely helped in the growth and development of the SKIMS, a shade of which is yet apparent. He showed a deep interest in the Health care delivery system and did studies on these to find solutions to problems of the health delivery system. In 1995, Prof. Khuroo joined Head & Consultant of Gastroenterology and Liver Transplantation at the prestigious King Faisal Hospital and Research Centre (KFSH) Riyadh Saudi Arabia. During 10 years he spend as a consultant gastroenterologist and hepatologist at KFSH he helped to set up a program of Liver Transplantation in the Kingdom of Saudi Arabia. Finally, his commitment to his soil brought him back to Kashmir in January 2005. 0n his return to Kashmir, India, he established a tertiary Care Digestive Diseases Center in Srinagar. Prof. Khuroo has received numerous national and international awards; traveled as a Guest Speaker to all major Institutions and conferences in the World, and received an honorary Fellowship of the Royal College of Physicians England (FRCP) and American College of Physicians (FACP). In 1995, American College of Physicians conferred the Coveted title of “Master of American College of Physicians (MACP)” to Prof. Khuroo. During his 35 years of teaching career Prof. Khuroo guided 21 MD/PhD projects and trained a huge group of clinicians in the art of Medicine and Gastroenterology.
Paul Martin is Professor of Medicine and Chief of the Division of Digestive Health and Liver Diseases at the University of Miami Miller School of Medicine, where he holds the Mandel Chair in Gastroenterology. He is a native of Dublin, Ireland, where he graduated with honors from medical school at University College, Dublin. He received a Doctorate in Medicine from the National University of Ireland. He did his initial training in internal medicine in Dublin completing a residency at the University of Alberta, Canada. After training in gastroenterology also in Canada he was a Medical Staff Fellow at the National Institutes of Health in Bethesda, Maryland.
His clinical activities include transplant and general hepatology. Dr Martin has had a major interest in the management of viral hepatitis in organ transplant. This extends not only to liver transplant patients with chronic viral hepatitis but also to other organ systems most notably renal. Dr Martin has been involved in a number of studies related to the impact of viral hepatitis in renal recipients as well the role of antiviral therapy in organ transplant recipients.
He has also published on transmission of viral hepatitis in patients with chronic kidney disease. He serves on the Board of the American Association for the Study of Liver Diseases. Dr Martin has authored or co-authored over 200 peer reviewed publications as well as review articles and chapters. In addition, he has edited a number of issues of the Clinics in Liver Disease. He is Editor Emeritus of Liver Transplanation.